PEGylated recombinant human growth hormone compounds

1. A method of treating a GH related disease comprising:

administering once weekly an effective amount of a recombinant human growth hormone (“rhGH”) PEGylated prodrug conjugate to a patient having a GH related disease;

wherein the rhGH PEGylated prodrug conjugate is of formula (I) or (II):

wherein

T represents hGH-NH;

X represents a spacer moiety;

Y 1 and Y 2 each independently represent O, S or NR 6 ;

Y 3 and Y 5 represents O or S, independently of each other;

Y 4 represents O, NR 6 or —C(R 7 )(R 8 );

R 2 and R 3 represent independently of each other a moiety selected from the group consisting of hydrogen, substituted or unsubstituted linear, branched or cyclical alkyl or heteroalkyl groups, aryls, substituted aryls, substituted or unsubstituted heteroaryls, cyano groups, nitro groups, halogens, carboxy groups, carboxyalkyl groups, alkylcarbonyl groups, and carboxamidoalkyl groups;

R 4 represents a moiety selected from the group consisting of hydrogen, substituted or unsubstituted linear, branched or cyclical alkyls or heteroalkyls, aryls, substituted aryls, substituted or unsubstituted heteroaryl, substituted or unsubstituted linear, branched or cyclical alkoxys, substituted or unsubstituted linear, branched or cyclical heteroalkyloxys, aryloxys or heteroaryloxys, cyano groups, and halogens;

R 7 and R 8 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted linear, branched or cyclical alkyls or heteroalkyls, aryls, substituted aryls, substituted or unsubstituted heteroaryls, carboxyalkyl groups, alkylcarbonyl groups, carboxamidoalkyl groups, cyano groups, and halogens;

R 6 represents a group selected from hydrogen, substituted or unsubstituted linear, branched or cyclical alkyls or heteroalkyls, aryls, substituted aryls, and substituted or unsubstituted heteroaryls;

R 1 is a polymeric carrier having at least 3 chains S 0 , S 1 and S 2 , wherein one or more of S 0 , S 1 and S 2 are polyethylene glycol based;

W represents a group selected from substituted or unsubstituted linear, branched or cyclical alkyls, aryls, substituted aryls, substituted or unsubstituted linear, branched or cyclical heteroalkyls, substituted or unsubstituted heteroaryls;

Nu represents a nucleophile;

n represents zero or a positive imager; and

Ar represents a multi-substituted aromatic hydrocarbon or multi-substituted aromatic heterocycle; and

wherein the molecular weight of the prodrug without the hGH-NH is at least 25 kDa and at most 1000 kDa.

2. The method of claim 1 ;

wherein the molecular weight of the prodrug without the hGH-NH is at least 25 kDa and at most 500 kDa.

3. The method of claim 1 ;

wherein the molecular weight of the prodrug without the hGH-NH is at least 30 and at most 250 kDa.

4. The method of claim 1 ;

wherein the molecular weigh of the prodrug without the hGH-NH is at least 30 kDa and at most 120 kDa.

5. The method of claim 1 ;

wherein the at least three chains S 0 , S 1 and S 2 are independently based on a polymer selected from the group consisting of polyalkyloxy polymers, hyaluronic acid and derivatives thereof, polyvinyl alcohols, polyoxazolines, polyanhydrides, poly(ortho esters), polycarbonates, polyurethanes, polyacrylic acids, polyacrylamides, polyacrylates, polymethacrylates, polyorganophosphazenes, polysiloxanes, polyvinylpyrrolidone, polycyanoacrylates, and polyesters; and

wherein one or more of S 0 , S 1 and S 2 are polyethylene glycol based.

6. The method of claim 1 ;

wherein S 0 , S 1 , and S 2 are based on a polyalkoxy polymer; and

wherein one or more of S 0 , S 1 and S 2 are polyethylene glycol based.

7. The method of claim 1 ;

wherein S 0 , S 1 , and S 2 are polyethylene glycol based.

8. The method of claim 1 ;

wherein the moiety

of formula (I) or (II) is selected from the group consisting of:

9. The method of claim 1 ;

wherein the moiety

is selected from the group consisting of:

10. The method of claim 1 ;

wherein the GH related disease is selected from the group consisting of growth hormone deficiency (“GHD”), adult onset growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, short bowel syndrome, chronic renal insufficiency, small for gestational age (“SGA”), AIDS wasting, anti-ageing, rheumatoid arthritis, idiopathic small stature, short stature homeobox gene, somatopause, Noonan syndrome, skeletal dysplasia, Down syndrome, short stature associated with prolonged steroid use, Aarskog's syndrome, chronic renal disease, juvenile rheumatoid arthritis, cystic fibrosis, HIV-infection in children receiving HAART treatment, short stature in children born with very low birth weight but SGA, skeletal dysplasia, hypochondroplasia, achondroplasia, idiopathic short stature, GHD in adults; fractures in or of long bones, fractures in or of spongious bones, patients after tendon or ligament surgery in hand, knee, or shoulder; distraction osteogenesis; disorders resulting from hip or discus replacement, meniscus repair, spinal fusions or prosthesis fixation; disorders resulting from fixing of osteosynthesis material; non-union or mal-union of fractures; disorders resulting from osteatomia; disorders resulting from graft implantation; articular cartilage degeneration in knee caused by trauma or arthritis; osteoporosis in patients with Turner syndrome; osteoporosis in men; adult patients in chronic dialysis (“APCD”); malnutritional associated cardiovascular disease in APCD; reversal of cachexia in APCD; cancer in APCD; chronic abstractive pulmonal disease in APCD; HIV in APCD; elderly with APCD; chronic liver disease in APCD, fatigue syndrome in APCD; Crohn's disease; impaired liver function; males with HIV infections; short bowel syndrome; central obesity; HIV-associated lipodystrophy syndrome; male infertility; patients after major elective surgery, alcohol/drug detoxification or neurological trauma; aging; frail elderly; osteo-arthritis; traumatically damaged cartilage; erectile dysfunction; fibromyalgia; memory disorders; depression; traumatic brain injury; subarachnoid haemorrhage; very low birth weight; metabolic syndrome; glucocorticoid myopathy; and short stature due to glucocorticoid treatment in children.

11. The method of claim 1 ;

wherein the GH related disease is growth hormone deficiency.

12. The method of claim 1 ;

wherein the GH related disease is one or more fractures in or of long bones selected from the group consisting of tibia, fibula, femur, humerus, radius, ulna, clavicula, matacarpea, matatarsea, and digit.

13. The method of claim 1 ;

wherein the GH related disease is one or more fractures in or of spongious bones selected from the group consisting of the scull, base of hand, and base of foot.